Compounded GLP-1 drugs creating concern among doctors and FDA
They're often cheaper and easier to get than Ozempic, but doctors say compounded GLP-1 drugs come with serious risks.
Read full article →Tracking Medicare news, policy, and coverage changes.
They're often cheaper and easier to get than Ozempic, but doctors say compounded GLP-1 drugs come with serious risks.
Read full article →KFF Health News is working to collect and post approved plans, by state, here and this database as more states respond to emails and public records requests for their documents.
Read full article →The tiny federal agency that tracks consumer product safety is pressuring hospitals to turn over patient records from emergency room visits, including about injuries that have nothing to do with consumer products.
Read full article →“Emergency departments across America report dramatic increases in serious injuries from e-bikes and e-scooters,” write CHOP’s J. Todd R. Lawrence and Madison A. Kesler.
Read full article →Even as some medical schools heed health secretary Robert F. Kennedy Jr.’s call for more nutrition education, several told STAT that they plan to steer clear of topics that aren’t…
Read full article →“I have come to believe that changing a mind is rarely the point. Planting a seed is,” writes nurse-midwife Mara Evans.
Read full article →Argenx plans to buy Forte Biosciences for $2.2 billion, expanding its pipeline of drugs that could treat multiple autoimmune diseases.
Read full article →Baltimore is rethinking what it means to call 911, and who responds. Callers who don't need police will get help finding social services and healthcare before they actually fall into crisis.
Read full article →NPR's A Martinez asks Dr. Jennifer Nuzzo of Brown University why there have been more measles cases this year so far than in all of last year, and what can be done to stop the resurgence.
Read full article →Healthcare AI has poured into the exam room, but choosing the right provider remains untouched.
Read full article →Crystalys’s dotinurad is currently in pivotal testing for gout, a prevalent inflammatory disorder with few treatment options. The drug has the same mechanism of action as a molecule that Sobi added to its pipeline through a $950 million acquisition. The post Crystalys Therapeutics Tacks On $130M for Pivotal Tests of Gout Drug appeared first on MedCity News .
Read full article →(MedPage Today) -- "What you're seeing here is pure censorship." -- Steven Kahn, MBChB, editor-in-chief of Diabetes Care, after American Diabetes Association (ADA) leadership blocked a collection of editorials discussing researchers' removal...
Read full article →